In scuba divers with large patent foramen ovale (PFO), transcatheter closure seems to prevent decompression sickness (DCS), a new study suggests. “According to our data, PFO closure is recommended in ...

The PREMIUM trial, which failed to show a benefit of patent foramen ovale (PFO) closure in patients with frequent migraines, is now in print. Responding to the publication this week, proponents of the ...

Abbott Laboratories ABT recently launched its Amplatzer Talisman PFO Occlusion System in Europe. The Talisman device aims to treat patent foramen ovale (PFO) patients who have had a stroke and are at ...

New data show zero device-related complications or atrial fibrillation, no recurrent stroke or TIA, with a cohort 40% larger than Gore and Amplatzer device studies FOUNTAIN VALLEY, Calif., Sept. 16, ...

Because the benefits of patent foramen ovale closure were once in question, physicians remain hesitant about its use in clinical practice. Recent data, however, have confirmed the safety and efficacy ...

Abbott Laboratories ABT recently received FDA approval for its Amplatzer Talisman PFO Occlusion System to treat patent foramen ovale (PFO) patients at risk of recurrent ischemic stroke. The ...

LOS ANGELES, CA – Percutaneous closure of patent foramen ovale (PFO) did not significantly curb migraine-attack frequency in patients with episodic migraine refractory to multiple medications in the ...

, a global medical device company, today announced the presentation of additional data from its landmark RESPECT trial at the American Stroke Association's International Stroke Conference 2013 in ...